Free Trial
NASDAQ:STTK

Shattuck Labs Q3 2026 Earnings Results & Report

Shattuck Labs logo
$4.88 -0.11 (-2.10%)
As of 02:16 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Shattuck Labs missed analyst earnings expectations in its Q3 2026 results, released November 5, 2026. The company reported EPS of -$0.14 versus the -$0.1053 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Shattuck Labs EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.1053
Beat/Miss
Missed by -$0.0348
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Shattuck Labs Revenue Results

Actual Revenue
N/A
Expected Revenue
$33 thousand
Beat/Miss
N/A
YoY Revenue Growth
N/A

Shattuck Labs Q3 2026 Earnings FAQ

Shattuck Labs (NASDAQ:STTK) reported earnings of -$0.14 per share for Q3 2026, missing the consensus estimate of -$0.1053. The report was announced on Thursday, November 5, 2026.

Shattuck Labs Earnings Headlines

Why Iran May Only Be the First Move
Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen. No cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.tc pixel
Piper Sandler Remains a Buy on Shattuck Labs (STTK)
UBS Initiates Shattuck Labs at Buy With $17 Price Target
See More Shattuck Labs Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Shattuck Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Shattuck Labs and other key companies, straight to your email.

About Shattuck Labs

Shattuck Labs (NASDAQ:STTK) is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company’s research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to combine immune-cell activation with checkpoint inhibition in a single therapeutic molecule.

Shattuck’s pipeline has included bifunctional fusion proteins such as SL-172154, an investigational therapy designed to engage CD40 ligand and block PD-L1, and SL-173154, which is designed to target CD27 ligand and PD-L1. These programs have been evaluated in clinical studies involving patients with advanced solid tumors and hematologic malignancies. The company’s drug candidates remain investigational and have not been approved for commercial use.

Founded in 2016, Shattuck Labs is based in Austin, Texas, and has maintained research and development operations in North Carolina. The company’s leadership has included co-founder Taylor Schreiber, M.D., Ph.D., who has served as president and chief executive officer. Shattuck Labs became a publicly traded company on the Nasdaq under the symbol STTK in 2020.

View Shattuck Labs Profile